Abstract: An implant, particularly a dental implant is provided, having an anchoring region (12) for anchoring in a bone, which preferably includes a thread (14) for screwing in the bone, and a fastening region (22) for attaching a supra-construction, wherein an abutment region (16) adjoins the anchoring region (12), the abutment region (16) having a guide structure with a plurality of outwardly projecting ridges (18) provided thereon, and preferably, grooves (20) being formed between the ridges (20). The guide structure of the anchoring region (12) allows a better osseointegration and counteracts periimplant bone loss.
Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents are listed in the description. Preferred compounds are those wherein X isoxygen, R1 is morpholino and R2 is substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
Abstract: Atomic force microscope measuring device comprising a micro-cantilever and an intensity modulated laser exciting the cantilever, wherein the measuring device comprises an optical microscope, in particular a fluorescence microscope, a confocal microscope, a fluorescence energy transfer (FRET) microscope, a DIC and/or phase contrast microscope, all of those in particular construed as an inverted microscope.
Type:
Application
Filed:
February 17, 2015
Publication date:
January 26, 2017
Applicants:
UNIVERSITÄT BASEL, ETH Zurich
Inventors:
David MARTINEZ-MARTIN, Daniel J. MUELLER, Sascha MARTIN, Christoph GERBER
Abstract: The present invention refers to lipophilic extracts of members of the Iridaceae family, such as Iris germanica and/or Iris pallida, that have been found to promote lymphatic function. These extracts are suitable for the treatment of skin inflammation, rheumatoid arthritis, impaired wound healing, chronic inflammatory diseases, chronic airway inflammation, inflammatory bowel disease, rosacea, primary and/or secondary lymphedemas. The most active components were found to be the iridals.
Type:
Application
Filed:
November 17, 2015
Publication date:
December 22, 2016
Applicants:
UNIVERSITAET BASEL, ETH ZUERICH
Inventors:
Michael Detmar, Matthias Hamburger, Olivier Potterat, Adriana Sliwa-Primorac
Abstract: Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, the therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.
Abstract: Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, the therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.
Abstract: Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, and therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.
Abstract: Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, and therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.